Browse SLAMF6

Summary
SymbolSLAMF6
NameSLAM family member 6
Aliases KALI; NTBA; KALIb; Ly108; SF2000; NTB-A; CD352; NK-T-B-antigen; NTBA receptor; activating NK receptor; natur ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF07686 Immunoglobulin V-set domain
Function

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Triggers cytolytic activity only in natural killer cells (NK) expressing high surface densities of natural cytotoxicity receptors (PubMed:11489943, PubMed:16920955). Positive signaling in NK cells implicates phosphorylation of VAV1. NK cell activation seems to depend on SH2D1B and not on SH2D1A (PubMed:16920955). In conjunction with SLAMF1 controls the transition between positive selection and the subsequent expansion and differentiation of the thymocytic natural killer T (NKT) cell lineage (By similarity). Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A (PubMed:22184727, PubMed:16920955). Promotes recruitment of RORC to the IL-17 promoter (PubMed:22989874). In conjunction with SLAMF1 and CD84/SLAMF5 may be a negative regulator of the humoral immune response. In the absence of SH2D1A/SAP can transmit negative signals to CD4(+) T-cells and NKT cells. Negatively regulates germinal center formation by inhibiting T-cell:B-cell adhesion; the function probably implicates increased association with PTPN6/SHP-1 via ITSMs in absence of SH2D1A/SAP. However, reported to be involved in maintaining B-cell tolerance in germinal centers and in preventing autoimmunity (By similarity).

> Gene Ontology
 
Biological Process GO:0001779 natural killer cell differentiation
GO:0001787 natural killer cell proliferation
GO:0001819 positive regulation of cytokine production
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001912 positive regulation of leukocyte mediated cytotoxicity
GO:0002228 natural killer cell mediated immunity
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002295 T-helper cell lineage commitment
GO:0002360 T cell lineage commitment
GO:0002363 alpha-beta T cell lineage commitment
GO:0002366 leukocyte activation involved in immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002715 regulation of natural killer cell mediated immunity
GO:0002717 positive regulation of natural killer cell mediated immunity
GO:0007159 leukocyte cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030101 natural killer cell activation
GO:0030217 T cell differentiation
GO:0031341 regulation of cell killing
GO:0031343 positive regulation of cell killing
GO:0031349 positive regulation of defense response
GO:0032609 interferon-gamma production
GO:0032620 interleukin-17 production
GO:0032649 regulation of interferon-gamma production
GO:0032660 regulation of interleukin-17 production
GO:0032729 positive regulation of interferon-gamma production
GO:0032740 positive regulation of interleukin-17 production
GO:0032943 mononuclear cell proliferation
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0042093 T-helper cell differentiation
GO:0042110 T cell activation
GO:0042267 natural killer cell mediated cytotoxicity
GO:0042269 regulation of natural killer cell mediated cytotoxicity
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043368 positive T cell selection
GO:0043369 CD4-positive or CD8-positive, alpha-beta T cell lineage commitment
GO:0043373 CD4-positive, alpha-beta T cell lineage commitment
GO:0045058 T cell selection
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045165 cell fate commitment
GO:0045954 positive regulation of natural killer cell mediated cytotoxicity
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046651 lymphocyte proliferation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0071593 lymphocyte aggregation
GO:0072538 T-helper 17 type immune response
GO:0072539 T-helper 17 cell differentiation
GO:0072540 T-helper 17 cell lineage commitment
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Summary
SymbolSLAMF6
NameSLAM family member 6
Aliases KALI; NTBA; KALIb; Ly108; SF2000; NTB-A; CD352; NK-T-B-antigen; NTBA receptor; activating NK receptor; natur ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLAMF6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SLAMF6 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29305520MelanomaPromote immunity (T/NK cell function); essential for immunotherapySoluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo. CD8+ T cells costimulated with seSLAMF6 secreted more IFNγ and displayed augmented cytolytic activity.
24510590Ovarian CarcinomaPromote immunity (T and NK cell function)Most tumor-associated NK cells displayed a CD56(bright) , CD16(neg) or CD56(bright) , CD16(dim) phenotype, and very poor cytolytic activities, despite an increased expression of the activation marker CD69. They also showed downregulation of DNAM-1, 2B4, and NTB-A activating receptors, and an altered chemokine receptor repertoire.
22156347MelanomaPromote immunity (T cell function)Specific blocking of NTB-A on APCs markedly reduced cytokine production by CD8 lymphocytes, pointing to a possible contribution of NTB-A costimulation to T cell functional diversity.
Summary
SymbolSLAMF6
NameSLAM family member 6
Aliases KALI; NTBA; KALIb; Ly108; SF2000; NTB-A; CD352; NK-T-B-antigen; NTBA receptor; activating NK receptor; natur ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLAMF6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLAMF6
NameSLAM family member 6
Aliases KALI; NTBA; KALIb; Ly108; SF2000; NTB-A; CD352; NK-T-B-antigen; NTBA receptor; activating NK receptor; natur ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLAMF6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0080.988
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6430.504
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.490.563
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0410.931
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5480.624
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6060.68
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9240.14
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.6010.141
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2020.864
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5820.0701
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5750.239
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0190.94
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLAMF6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolSLAMF6
NameSLAM family member 6
Aliases KALI; NTBA; KALIb; Ly108; SF2000; NTB-A; CD352; NK-T-B-antigen; NTBA receptor; activating NK receptor; natur ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLAMF6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLAMF6
NameSLAM family member 6
Aliases KALI; NTBA; KALIb; Ly108; SF2000; NTB-A; CD352; NK-T-B-antigen; NTBA receptor; activating NK receptor; natur ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLAMF6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLAMF6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLAMF6
NameSLAM family member 6
Aliases KALI; NTBA; KALIb; Ly108; SF2000; NTB-A; CD352; NK-T-B-antigen; NTBA receptor; activating NK receptor; natur ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLAMF6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLAMF6
NameSLAM family member 6
Aliases KALI; NTBA; KALIb; Ly108; SF2000; NTB-A; CD352; NK-T-B-antigen; NTBA receptor; activating NK receptor; natur ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLAMF6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLAMF6
NameSLAM family member 6
Aliases KALI; NTBA; KALIb; Ly108; SF2000; NTB-A; CD352; NK-T-B-antigen; NTBA receptor; activating NK receptor; natur ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLAMF6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLAMF6
NameSLAM family member 6
Aliases KALI; NTBA; KALIb; Ly108; SF2000; NTB-A; CD352; NK-T-B-antigen; NTBA receptor; activating NK receptor; natur ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLAMF6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.